期刊
NATURE MEDICINE
卷 23, 期 2, 页码 200-212出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4266
关键词
-
资金
- Spanish Ministerio de Economia, Industria y Competitividad (MINECO)
- Pro-CNIC Foundation
- Severo Ochoa Center of Excellence (MINECO award) [SEV-2015-0505]
- MINECO [SAF2013-45258P, SAF2012-34296, SAF2015-636333R]
- Fundacion La Marato (TV3 grant) [20151331, 20151330]
- CSIC
- CIBERCV of Ministerio de Sanidad [B16/11/00264]
- Red de Investigacion Cardiovascular (RIC) of Ministerio de Sanidad [RD12/0042/0022, RD12/0042/0021, RD12/0042/0024, RD12/0042/0056, RD12/0042/0018]
- Marie Sklodowska-Curie fellowship
- FPI fellowships [BES 2010-034552, SVP-2013-067777]
Heritable thoracic aortic aneurysms and dissections (TAAD), including Marfan syndrome (MFS), currently lack a cure, and causative mutations have been identified for only a fraction of affected families. Here we identify the metalloproteinase ADAMTS1 and inducible nitric oxide synthase (NOS2) as therapeutic targets in individuals with TAAD. We show that Adamts1 is a major mediator of vascular homeostasis, given that genetic haploinsufficiency of Adamts1 in mice causes TAAD similar to MFS. Aortic nitric oxide and Nos2 levels were higher in Adamts1-deficient mice and in a mouse model of MFS (hereafter referred to as MFS mice), and Nos2 inactivation protected both types of mice from aortic pathology. Pharmacological inhibition of Nos2 rapidly reversed aortic dilation and medial degeneration in young Adamts1-deficient mice and in young or old MFS mice. Patients with MFS showed elevated NOS2 and decreased ADAMTS1 protein levels in the aorta. These findings uncover a possible causative role for the ADAMTS1 NOS2 axis in human TAAD and warrant evaluation of NOS2 inhibitors for therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据